Biotechnology

Imac

Palantir

Financial Analysis

PLTR

TECH

BEAT

BACK

BEATW

<p><span class="security-tag" type="security-tag" counter_id="ST/US/PLTR" name="Palantir Tech" trend="">$Palantir Tech(PLTR.US)</span> released its Q3 2025 earnings after the market closed on November 3rd, Eastern Time. Overall, the Q2 performance remains impressive. Although the guidance and operational indicators imply signs of slowing down, considering the management's consistently conservative guidance style and the short-term changes in the U.S. Department of Defense procurement process, the short-term disturbances are not a major issue. However, with a full valuation, the market will be more critical of Palantir. Reviewing past performance versus market reactions, it is not difficult to find that from the three quarters starting this year, as the valuation rises...</p>

Palantir Tech

Bio-Techne

Mirae Asset Global Investments Co., Ltd.

HeartBeam

First Commonwealth Financial PA

HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM)

Palantir: Expensive Valuation is Biting Back!

Imac released FY2025 9 Months Earnings on December 17 (EST), actual revenue USD 22.72 K, actual EPS USD -3.1225

Imac released FY2025 Q3 earnings on December 17 (EST), actual revenue USD 21.22 K, actual EPS USD -1.1493 (forecast EPS USD -0.87)

Imac released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 1.5K, actual EPS USD -1.9541

Imac released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8886 (forecast USD -0.87)

IMAC Holdings Inc. Secures Unsecured Promissory Note Financing

Imac released FY2025 Q1 earnings on July 1 (EST), actual revenue USD 1.5 K (forecast USD 0), actual EPS USD -1.0844 (forecast USD -0.87)

IMAC Holdings Inc. Obtains Unsecured Loan

IMAC Holdings Receives $301,000 Unsecured Promissory Note

IMAC Holdings Receives a $455,000 Unsecured Promissory Note from Lender

IMAC Holdings Delays Q1 2025 Quarterly Report

IMAC Holdings Secures $275,800 Unsecured Promissory Note Financing

IMAC Holdings Switches Accounting Firm

Imac released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.9125 (forecast USD -0.87)

Imac released FY2024 Annual Earnings on April 15 (EST), actual revenue USD 72.05 K (forecast USD 0), actual EPS USD -5.763 (forecast USD -2.53)

IMAC Holdings Establishes New Subsidiary Ignite Proteomics Focused on Cancer Treatment

Imac released FY2024 Q3 earnings on January 17, 2025 (EST), actual revenue USD 56.3 K (forecast USD 0), actual EPS USD -1.7613 (forecast USD -0.87)

Imac released FY2024 9 Months earnings on January 17 Post-Market (EST), actual revenue USD 72.05 K, actual EPS USD -4.0178

Imac released FY2024 Semi-Annual earnings on December 18 (EST), actual revenue USD 15.75 K, actual EPS USD -2.2733

Imac released FY2024 Q2 earnings on December 18 (EST), actual revenue 15.75 K USD, actual EPS -1.7196 USD (forecast EPS -0.44 USD)

IMAC Holdings Receives Notice from NASDAQ Regarding Delay in Submitting 10-Q Form

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap